ES2113923T3 - Conjugados. - Google Patents

Conjugados.

Info

Publication number
ES2113923T3
ES2113923T3 ES92306149T ES92306149T ES2113923T3 ES 2113923 T3 ES2113923 T3 ES 2113923T3 ES 92306149 T ES92306149 T ES 92306149T ES 92306149 T ES92306149 T ES 92306149T ES 2113923 T3 ES2113923 T3 ES 2113923T3
Authority
ES
Spain
Prior art keywords
conjugates
antibody
toxin
treatment
tumors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92306149T
Other languages
English (en)
Inventor
Andrew Firman Wright
David Charles Blakey
John Edward Fitton
Peter Lind
Leif Lindholm
Jan Holmgren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syngenta Ltd
Pfizer Health AB
Original Assignee
Zeneca Ltd
Pharmacia and Upjohn AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeneca Ltd, Pharmacia and Upjohn AB filed Critical Zeneca Ltd
Application granted granted Critical
Publication of ES2113923T3 publication Critical patent/ES2113923T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Semiconductor Lasers (AREA)
  • Bipolar Transistors (AREA)
  • Metal-Oxide And Bipolar Metal-Oxide Semiconductor Integrated Circuits (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Seasonings (AREA)

Abstract

LOS CONJUGADOS UTILES PARA EL TRATAMIENTO DE TUMORES GASTROINTESTINALES TALES COMO LOS TUMORES COLORRECTALES COMPRENDE UN ANTICUERPO COMO EL ANTICUERPO C242 Y UNA TOXINA COMO LA RICINA A. SE PUEDEN ACOPLAR EL ANTICUERPO Y LA TOXINA MEDIANTE UN ENLACE. TAMBIEN SE INCLUYEN LAS COMPOSICIONES FARMACEUTICAS QUE CONTIENEN LOS CONJUGADOS Y LOS PROCESOS PARA SU PREPARACION, ASI COMO LOS METODOS DE TRATAMIENTO DE LOS TUMORES GASTROINTESTINALES.
ES92306149T 1991-07-03 1992-07-03 Conjugados. Expired - Lifetime ES2113923T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919114399A GB9114399D0 (en) 1991-07-03 1991-07-03 Conjugates

Publications (1)

Publication Number Publication Date
ES2113923T3 true ES2113923T3 (es) 1998-05-16

Family

ID=10697775

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92306149T Expired - Lifetime ES2113923T3 (es) 1991-07-03 1992-07-03 Conjugados.

Country Status (24)

Country Link
EP (1) EP0528527B1 (es)
JP (1) JP3735379B2 (es)
KR (1) KR100252147B1 (es)
AT (1) ATE164768T1 (es)
AU (1) AU665546B2 (es)
CA (1) CA2073113C (es)
CZ (1) CZ209792A3 (es)
DE (1) DE69225035T2 (es)
DK (1) DK0528527T3 (es)
ES (1) ES2113923T3 (es)
FI (1) FI106928B (es)
GB (2) GB9114399D0 (es)
GR (1) GR3026575T3 (es)
HU (1) HU215243B (es)
IE (1) IE922190A1 (es)
IL (1) IL102399A (es)
MY (1) MY110513A (es)
NO (1) NO308539B1 (es)
NZ (1) NZ243437A (es)
PT (1) PT100660B (es)
SK (1) SK209792A3 (es)
TW (1) TW329425B (es)
ZA (1) ZA924973B (es)
ZW (1) ZW10192A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5686121A (en) * 1979-12-14 1981-07-13 Teijin Ltd Antitumor proten complex and its preparation
ATE68703T1 (de) 1984-02-08 1991-11-15 Cetus Corp Toxinkonjugate.
US5165923A (en) * 1989-11-20 1992-11-24 Imperial Cancer Research Technology Methods and compositions for the treatment of hodgkin's disease
DK0610179T3 (da) * 1990-07-20 1997-03-24 Pharmacia & Upjohn Ab Målspecifikke antistof-superantigenkonjugater og fremstilling deraf

Also Published As

Publication number Publication date
NO308539B1 (no) 2000-09-25
AU1943092A (en) 1993-01-07
NZ243437A (en) 1994-10-26
HU9202219D0 (en) 1992-10-28
FI923085A0 (fi) 1992-07-03
EP0528527B1 (en) 1998-04-08
ZW10192A1 (en) 1993-03-31
CA2073113A1 (en) 1993-01-04
IL102399A0 (en) 1993-01-14
CZ209792A3 (en) 1993-01-13
CA2073113C (en) 2004-09-14
EP0528527A3 (en) 1993-03-17
GB9212880D0 (en) 1992-07-29
NO922383D0 (no) 1992-06-17
SK209792A3 (en) 1994-06-08
ZA924973B (en) 1993-04-28
TW329425B (en) 1998-04-11
HUT67048A (en) 1995-01-30
FI923085L (fi) 1993-01-04
MY110513A (en) 1998-07-31
AU665546B2 (en) 1996-01-11
KR930001928A (ko) 1993-02-22
DE69225035D1 (de) 1998-05-14
NO922383L (no) 1993-01-04
KR100252147B1 (ko) 2000-09-01
JPH05320065A (ja) 1993-12-03
IL102399A (en) 2003-05-29
PT100660A (pt) 1993-10-29
HU215243B (hu) 1998-11-30
FI106928B (fi) 2001-05-15
DE69225035T2 (de) 1998-08-13
JP3735379B2 (ja) 2006-01-18
PT100660B (pt) 1999-06-30
EP0528527A2 (en) 1993-02-24
ATE164768T1 (de) 1998-04-15
DK0528527T3 (da) 1999-01-18
GR3026575T3 (en) 1998-07-31
GB9114399D0 (en) 1991-08-21
IE922190A1 (en) 1993-01-13

Similar Documents

Publication Publication Date Title
ATE7920T1 (de) Rapamycin-derivate.
ES2110230T3 (es) Ensayo de rapamicina.
AR005703A1 (es) Oxazolidinonas sustituidas, procedimiento para su preparacion, uso de las mismas para preparar medicamentos y medicamentos que las contienen
MX9207074A (es) Piperazinil- y piperidinil -ciclohexanoles y composicion farmaceutica que los comprende
MX9206306A (es) Peptidos, procedimiento para su produccion y composicion farmaceutica que los contiene.
NL980012I2 (nl) Mometasonfuroaat-monohydraat, werkwijze om zulks te bereiden en farmaceutische samenstellingen.
SE7613959L (sv) Antibiotisk komposition och forfarande for framstellning derav
MX9102500A (es) Compuestos de bifenilio, procedimiento para su preparacion y composicion farmaceutica que los contiene.
IT8019740A0 (it) Derivati benzoazepinici.
SE8002831L (sv) Oxitetracyklinberedningar
MX9305998A (es) 6-heterociclic-4-amino-1, 3, 4, 5,-tetrahidrobenz[cd] indoles yprocedimiento para su preparacion.
ITMI912745A0 (it) Derivati 5h-benzodiazepinici, composizioni farmaceutiche che li contengono e procedimento per la loro preparazione.
ES2184761T3 (es) Derivados de taxanos c10 y composiciones farmaceuticas.
ES2104917T3 (es) Bis-naftalimidas que contienen engarces amido y tioamido como agentes anticancerosos.
ES2113923T3 (es) Conjugados.
SE7603223L (sv) 13,14-dehydro-11-deoxi-prostaglandiner och forfarande for deras framstellning
SE8306225D0 (sv) 2-piperazinyl-quinazoline derivatives, their production and pharmaceutical compositions containing them
ATE235902T1 (de) Immunmodulatorische azaspirane
ES2136965T3 (es) Derivados de 17-hidroxiiminoalquil y 17-hidroxiiminometilalquenil ciclopentanperhidrofenantreno activos sobre el sistema cardiovascular un procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
MX9206365A (es) Tetrahidrobenzotienopiridinas,proceso para su preparacion y composicion farmaceutica que las contiene
FI833443A0 (fi) 1,2,3,4-tetrahydro-1-aminometyl-4-fenylisokinoliner och foerfaranden foer framstaellning av dem
JPS51127887A (en) Guide device for transportable heatsealers
ECSP992866A (es) Derivados de sulfonamida
MX9302324A (es) Antagonistas de endotelina ii.
IT7922319A0 (it) Derivati n-fenetilimidazolici e,procedimento per la loro preparazione.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 528527

Country of ref document: ES